Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 4/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10331938 | 1.00 | RNASE1 (0.45) | RNASE1DNMT1ADRB1TK1P2RY1 | |
| SCHEMBL19464715 | 0.92 | RNASE1 (0.43) | RNASE1DNMT1ADRB1TK1DNMT3B | |
| SCHEMBL30817489 | 0.92 | RNASE1 (0.43) | RNASE1DNMT1ADRB1TK1DNMT3B | |
| SCHEMBL17052648 | 0.92 | RNASE1 (0.43) | RNASE1DNMT1ADRB1TK1DNMT3B | |
| SCHEMBL17056236 | 0.92 | RNASE1 (0.43) | RNASE1DNMT1ADRB1TK1DNMT3B | |
| SCHEMBL19884492 | 0.91 | P2RY1 (0.42) | TK1P2RY1 | |
| SCHEMBL24517423 | 0.89 | RNASE1 (0.46) | RNASE1DNMT1ADRB1TK1DNMT3B | |
| SCHEMBL13646172 | 0.88 | RNASE1 (0.46) | RNASE1DNMT1ADRB1TK1DNMT3B | |
| SCHEMBL31685415 | 0.88 | DNMT1 (0.45) | DNMT1ADRB1DNMT3BPOLB | |
| SCHEMBL14773848 | 0.88 | RNASE1 (0.46) | RNASE1DNMT1ADRB1TK1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| EP-4594491-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | Contera Pharma A/S (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-20250236871-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | disclosed |
| US-12221607-B2 | Multi-targeted single entity conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240116973-A1 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024068997-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2024-04-04 | — | — | WO | disclosed |
| US-20220106593-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3919619-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | Alnylam Pharmaceuticals, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3324980-B1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11053495-B2 | Multi-targeted single entity conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20180208927-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20050003378-A1 | Inhibitor of demethylase, antitumorigenic agent, and an in vitro assay for demethylase inhibitors | MCGILL UNIVERSITY (CA) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236871-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | SNRPE, DDX21, RNMT | RNASE1 40/4885DNMT1 327/4885ADRB1 3762/4885 |
| US-20220106593-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | SNRPE, DDX21, RNMT | RNASE1 40/4885DNMT1 327/4885ADRB1 3762/4885 |
| US-12221607-B2 | Multi-targeted single entity conjugates | SNRPE, DDX21, RNMT | RNASE1 40/4885DNMT1 327/4885ADRB1 3762/4885 |
| US-20240116973-A1 | MODIFIED OLIGONUCLEOTIDES | ADAR, EIF2AK2, TRDMT1 | RNASE1 5/4885DNMT1 111/4885ADRB1 4661/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | RNASE1 3/4885DNMT1 3133/4885ADRB1 4506/4885 |
| US-11053495-B2 | Multi-targeted single entity conjugates | SNRPE, DDX21, RNMT | RNASE1 40/4885DNMT1 327/4885ADRB1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.